CDXS - Codexis, Inc.
22.45 +0.53 (2.42%)
After hours: 5:49PM EST
| Previous Close | 21.79 |
| Open | 21.88 |
| Bid | 21.00 x 1300 |
| Ask | 22.45 x 900 |
| Day's Range | 21.46 - 21.95 |
| 52 Week Range | 8.85 - 23.05 |
| Volume | 469,497 |
| Avg. Volume | 469,555 |
| Market Cap | 1.184B |
| Beta (3Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.08 |
- GlobeNewswire•yesterday
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
Codexis, Inc. (CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder. Nestlé Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. CDX-6114 is Codexis’ first internally developed biotherapeutic product candidate.
- GlobeNewswire•9 days ago
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
Codexis, Inc. (CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova® Tablets, a novel, once-daily treatment for overactive bladder. “Our CodeEvolver® technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment. This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis President and CEO John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing.
- Investor's Business Daily•10 days ago
A Pact With Merck Sent This Biotech Stock Zooming Near A Breakout
Codexis stock approached a breakout Tuesday after the biotech company struck a deal with Dow Jones giant Merck for its protein-engineering technology. The platform is called CodeEvolver.
- Motley Fool•10 days ago
Here's Why Codexis Gained as Much as 9.8% Today
The enzyme leader announced a new and improved technology licensing deal with pharma giant Merck.
- Benzinga•10 days ago
The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
- GlobeNewswire•11 days ago
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
REDWOOD CITY, Calif., Feb. 04, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a.
- Motley Fool•16 days ago
3 Top Stocks Under $20
BlackBerry, Kinder Morgan, and Codexis could all have plenty of room to run.
- Motley Fool•last month
2 Top Small-Cap Stocks to Buy in January
A down-on-its-luck fertilizer company and an exceptionally diversified biotech are solid investments for 2019.
- Simply Wall St.•last month
Do Institutions Own Codexis, Inc. (NASDAQ:CDXS) Shares?
Every investor in Codexis, Inc. (NASDAQ:CDXS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CDXS earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Codexis Inc Earnings Call
- GlobeNewswire•3 months ago
Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•3 months ago
This Small-Cap Biotech is Quietly Setting the Stage For a Big 2019
Codexis is on pace to become the first publicly-traded synthetic biology company to deliver consistent operating profits. Investors should take note.
- Simply Wall St.•3 months ago
Should You Worry About Codexis Inc’s (NASDAQ:CDXS) CEO Pay?
In 2012 John Nicols was appointed CEO of Codexis Inc (NASDAQ:CDXS). First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap Read More...
- Zacks•3 months ago
Codexis (CDXS) Reports Break-Even Earnings for Q3
Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Codexis: 3Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 4 cents. Earnings, adjusted for stock option expense and non-recurring costs, were less than 1 cent on a per-share ...
- Zacks•3 months ago
Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•4 months ago
Better Synthetic Biology Stock: Amyris vs. Codexis
Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CDXS earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Codexis Inc Earnings Call
- Zacks•5 months ago
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
